Safety of propofol use in children and adolescents: A disproportionality analysis of the Food and Drug Administration adverse event reporting system (FAERS)

被引：0
|
作者：
Li, Hailong [1 ]
Bo, Zhenyan [1 ]
Zhang, Lingli [1 ]
机构：
[1] Sichuan Univ, West China Univ Hosp 2, Dept Pharm, Chengdu, Sichuan, Peoples R China
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2021年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：334 / 335
页数：2
相关论文
共 50 条
  • [11] Disproportionality Analysis of Safety with Nafcillin and Oxacillin with the FDA Adverse Event Reporting System (FAERS)
    Timbrook, Tristan T.
    McKay, Lydia
    Sutton, Jesse D.
    Spivak, Emily S.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (03)
  • [12] Antibiotics-associated pseudomembranous colitis: a disproportionality analysis of the US food and drug administration adverse event reporting system (FAERS) database
    Chen, Jinhua
    Yu, Weijiang
    Zhang, Wancun
    Sun, Cuicui
    Zhang, Wenzhou
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (10) : 1359 - 1365
  • [13] A real-world disproportionality analysis of the US Food and Drug Administration (FDA) adverse event reporting system (FAERS) events for Durvalumab
    Zou, Ting
    Li, Zhuoyang
    Wang, Tianhong
    Deng, Shuang
    Wang, Siman
    Hua, Yusi
    BMC PHARMACOLOGY & TOXICOLOGY, 2024, 25 (01):
  • [14] Associations of acute kidney injury with oral anticoagulants: a disproportionality analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) database
    Bai, Hehe
    Wang, Jinping
    Nie, Xiaojing
    Li, Huan
    Ma, Li
    Han, Xiaonian
    Peng, Lirong
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [15] Comment on: "Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database"
    Putzke, Joerg
    Haughie, Scott
    Zou, Kelly H.
    Ranganna, Gopinath M.
    BIODRUGS, 2021, 35 (03) : 373 - 374
  • [16] Safety of marketed biosimilar monoclonal antibody cancer treatments in the US: a disproportionality analysis using the food and drug administration adverse event reporting system (FAERS) database
    Xue, Xiangzhong
    Qian, Jingjing
    EXPERT OPINION ON DRUG SAFETY, 2025, 24 (01) : 59 - 68
  • [17] Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS)
    Kong, Wenqiang
    Mao, Wei
    Zhang, Lin
    Wu, Yanyan
    FRONTIERS IN PEDIATRICS, 2023, 10
  • [18] Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
    He, Chang-Zhu
    Qiu, Qin
    Lu, Song-Jie
    Xue, Fu-Li
    Liu, Jun-Qiao
    He, Yu
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [19] Reporting of pancreatitis with tocilizumab use: A disproportionality analysis using the United States Food and Drug Administration adverse event reporting system
    Kamath, Ashwin
    Acharya, Sahana
    Rao, Rashmi
    Ullal, Sheetal
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 324 - 324
  • [20] Comparison of the safety profiles for pirfenidone and nintedanib: a disproportionality analysis of the US food and drug administration adverse event reporting system
    Sun, Xiangyu
    Wang, Huaguang
    Zhan, Xi
    Yan, Yuanyuan
    Chen, Kun
    An, Zhuoling
    Zhou, Hong
    FRONTIERS IN PHARMACOLOGY, 2024, 15
12345